About Valeritas
Valeritas is a Healthcare company based in Bridgewater (United States) founded in 2003, and was acquired by Zealand Pharma in February 2020. Wearable insulin patch pumps are developed for transdermal delivery. Valeritas has raised $181.36 million across 6 funding rounds from investors including Welsh, Carson, Anderson & Stowe, Zealand Pharma and Abingworth. The company has 141 employees. Valeritas has completed 1 acquisition, including Andover. Valeritas offers products and services including Afrezza, V-Go, and Technosphere. Its focus areas include Life Sciences, Drug Delivery, Patches and Diabetes. Its legal entity is MannKind Corporation. Its competitors include scPharmaceuticals, Incline Therapeutics and VeraDermics; 3 of its 3 listed competitors have raised funding.
Company details
Valeritas was founded in 2003 in Bridgewater, United States, within the medical devices sector focused on diabetes management. Wearable insulin patch pumps are produced for skin-based insulin delivery, holding a one-day supply of fast-acting insulin. Continuous preset basal rates are used for release, supplemented by on-demand bolus dosing at mealtimes. Programmability and electricity are not required in the devices, with preset options available for varying daily insulin amounts.
- Headquarters Bridgewater, United States
- Employees 141
- Stage Acquired
- SectorsHealthcare
- Website valeritas.com
- Social LinkedIn X
- Acquired by Zealand Pharma (Feb 2020)
- Legal Name Mannkind Corporation
- Total Equity Funding$181.36M (USD)
in 6 rounds
- Latest Funding Round$25.2M (USD), Post-IPO
May 2016
- InvestorsWelsh, Carson, Anderson & Stowe
& 13 more
- Employee Count141
- Investments & Acquisitions
- Acquired byZealand Pharma
(Feb 2020)
Products & Services of Valeritas
Valeritas offers a comprehensive portfolio of products and services, including Afrezza, V-Go, and Technosphere.
Inhaled powder for managing diabetes blood sugar levels.
Patch device for continuous insulin administration.
Platform for delivering drugs via inhalation.
Funding Insights of Valeritas
Valeritas has successfully raised a total of $181.36M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.2 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $181.36M
- Total Rounds 6
- Last Round Post-IPO — $25.2M
- First Round $50M
(Nov 2008)
- Investors Count 13
All 6 funding rounds of Valeritas with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2016 | $25.2M | Post-IPO | – | – | |
| Jul 2014 | $21.95M | Series D | – | – | – |
| Jun 2013 | $100M | Debt – Conventional | – | – | |
| Sep 2011 | $150M | Series C | – | Welsh, Carson, Anderson & Stowe | |
| Apr 2011 | $9.4M | Series A | – | – | – |
| Nov 2008 | $50M | Debt – Convertible | – | – |
14 investors in total: 14 institutional.
Investors in Valeritas
Valeritas has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Welsh, Carson, Anderson & Stowe, Zealand Pharma and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Early-stage investments in US tech and life sciences are targeted. | montrosecapital.com | Miami, United States | ||
Venture capital investments in tech and healthtech sectors through dedicated funds. | pitango.com | |||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
VC firm making investment in early stage startups in the US | atvcapital.com | Menlo Park, United States | ||
Early stage VC firm investing in the US | onset.com | Menlo Park, United States | ||
VC firm investing in expansion stage tech and life sciences companies in the US | hlmvp.com | Waltham, United States | ||
Tech and Life Sciences focused corporate VC firm investing in the US | kpventures.com | Oakland, United States | ||
Growth capital is provided to mature MedTech companies by Agate. | agate-invest.com | Tel-Aviv, Israel | ||
Early stage healthcare services investments are facilitated by CHL. | chlmedical.com | Westport, United States |
Investor details for Valeritas
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Valeritas
12 people are tracked at Valeritas (6 in leadership, 6 in team); the tracked headcount is 141.
| Name | Role | Group |
|---|---|---|
Dave Lewis | Vice President, Marketing | Leadership |
Matthew Nguyen | Chief Commercial Officer | Leadership |
Doug Winkler | National Account Director | Leadership |
Ralph Barisano | VP Quality And Regulatory | Leadership |
Joseph Saldanha | Chief Business Officer | Leadership |
Chris Gregory | VP, R&D | Leadership |
Kerry McMullen | Sr. Operations Program Manager | Team |
Geoffrey Jenkins | EVP, Manufacturing, Operations, and R&D | Team |
Hoeun Pok | Post Market Surveillance | Team |
Christy Shearer | Regional Business Leader | Team |
William Tabia | Sr. Mechanical Inspector | Team |
Tommy Li | Asian Contract Manufacturing Manager | Team |
Complete people profiles for Valeritas
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Valeritas
Valeritas has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Andover.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Limited information is provided on core activities. | andover.net | 1996 | Jan 2002 | $1.04B |
Complete acquisition details for Valeritas
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Valeritas
6 dated milestones of Valeritas across 18 years, from founding to its latest funding, stage changes and deals.
- Acquisition Acquires Andover.
- Founded Valeritas is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Post-IPO, of $25.2M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Zealand Pharma.
Competitors of Valeritas
Valeritas has 3 listed competitors in our database, 3 of them funded. They include scPharmaceuticals, Incline Therapeutics and VeraDermics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scpharmaceuticals.com | 2013 | Lexington, United States | $78.75M | 96 | Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure | |
| inclinethera.com | 2009 | Redwood, United States | $43.94M | Hospital-focused specialty pharmaceuticals are developed for acute pain management. | ||
| veradermics.com | 2020 | San Antonio, United States | $262.71M | Drug-delivery platforms for pediatric wart treatments are developed. |
Detailed competitors of Valeritas
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Valeritas
Websites that share an audience with Valeritas (valeritas.com).
Websites whose visitors overlap most with Valeritas. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| catalent.com | 100% | 116.7K | #338,870 | View details | |
| apricusbio.com | 99% | View details | |||
valeant.com | valeant.com | 70% | – | ||
| khandelwallab.com | 63% | 6.5K | #1,877,524 | View details | |
| go-vgo.com | 62% | 3.9K | #4,575,736 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Valeritas
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Valeritas (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Valeritas
Complete news archive for Valeritas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Valeritas
Valeritas was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Valeritas is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Valeritas is a funded company, having raised a total of $181.36M across 6 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $50M, raised on Nov 2008.
Valeritas has 141 employees.
Valeritas was founded in 2003 in Bridgewater, United States, within the medical devices sector focused on diabetes management. Wearable insulin patch pumps are produced for skin-based insulin delivery, holding a one-day supply of fast-acting insulin. Continuous preset basal rates are used for release, supplemented by on-demand bolus dosing at mealtimes. Programmability and electricity are not required in the devices, with preset options available for varying daily insulin amounts.
Valeritas's top competitors include scPharmaceuticals, VeraDermics and Incline Therapeutics.
Valeritas offers Afrezza, V-Go, and Technosphere.
Valeritas has made 1 acquisition, including Andover.
Valeritas has 14 investors. Key investors include Welsh, Carson, Anderson & Stowe, Zealand Pharma, Abingworth, CRG, and Montrose Capital Partners.
Valeritas operates through Mannkind Corporation.
Yes. Valeritas was acquired by Zealand Pharma in February 2020.